These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36883059)

  • 21. HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis.
    Ma S; Ma Y; Qi F; Lei J; Chen F; Sun W; Wang D; Zhou S; Liu Z; Lu Z; Zhang D
    World J Surg Oncol; 2023 Sep; 21(1):293. PubMed ID: 37718459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
    Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
    J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of granulocyte macrophage-colony stimulating factor and its receptor in the synovium of osteoarthritis patients is negatively correlated with pain.
    van Helvoort EM; Eijkelkamp N; Lafeber FPJG; Mastbergen SC
    Rheumatology (Oxford); 2020 Nov; 59(11):3452-3457. PubMed ID: 32365364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
    Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
    BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High expression of CCDC6 in relation to unfavorable outcome and immune cells infiltration in hepatobiliary carcinoma.
    Wu T; Jiang X; Xu B; Zhong Q; Zheng J; Zhang X; Wang Y
    J Cancer; 2022; 13(12):3378-3395. PubMed ID: 36186907
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Modulation of expression of human GM-CSF and GM-CSFRalpha by total saponins of Panax ginseng].
    Wang SL; Chen D; Wang YP; Liu YG; Jiang R
    Sheng Li Xue Bao; 2003 Aug; 55(4):487-92. PubMed ID: 12937833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor ratio of unsaturated to saturated sulfatide species is associated with disease-free survival in intrahepatic cholangiocarcinoma.
    Huizing L; Chen L; Roeth AA; Heij LR; Flinders B; Bouwense SAW; Balluff B; Neumann UP; Heeren RMA; Olde Damink SWM; Vreeken RJ; Schaap FG
    Cell Oncol (Dordr); 2023 Jun; 46(3):629-642. PubMed ID: 36630049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
    Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
    Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
    Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
    Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal-associated invariant T-cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
    Zimmer CL; Filipovic I; Cornillet M; O'Rourke CJ; Berglin L; Jansson H; Sun D; Strauss O; Hertwig L; Johansson H; von Seth E; Sparrelid E; Dias J; Glaumann H; Melum E; Ellis EC; Sandberg JK; Andersen JB; Bergquist A; Björkström NK
    Hepatology; 2022 May; 75(5):1154-1168. PubMed ID: 34719787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ARHGAP21 Is Involved in the Carcinogenic Mechanism of Cholangiocarcinoma: A Study Based on Bioinformatic Analyses and Experimental Validation.
    Wang Z; Wu S; Wang G; Yang Z; Zhang Y; Zhu C; Qin X
    Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676763
    [No Abstract]   [Full Text] [Related]  

  • 34. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
    Sasaki M; Sato Y; Nakanuma Y
    Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annexin A1 Is a Potential Prognostic Marker for, and Enhances the Metastasis of, Cholangiocarcinoma.
    Kotepui KU; Obchoei S; Vaeteewoottacharn K; Okada S; Wongkham S; Sawanyawisuth K
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):715-721. PubMed ID: 35225485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling.
    Wei Y; Chen W; Li Z; Xie K; Liu F
    FASEB J; 2022 Dec; 36(12):e22647. PubMed ID: 36350008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alteration of galectin-1 during tumorigenesis of Opisthorchis viverrini infection-induced cholangiocarcinoma and its correlation with clinicopathology.
    Wu Z; Boonmars T; Nagano I; Boonjaraspinyo S; Pinlaor S; Pairojkul C; Chamgramol Y; Takahashi Y
    Tumour Biol; 2012 Aug; 33(4):1169-78. PubMed ID: 22373585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma.
    Tian F; Li D; Chen J; Liu W; Cai L; Li J; Jiang P; Liu Z; Zhao X; Guo F; Li X; Wang S
    Eur J Cancer; 2013 May; 49(7):1771-80. PubMed ID: 23313142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction of a prediction model for postoperative prognosis in patients with resectable cholangiocarcinoma based on silence information regulator 2 expression.
    Wang W; Ji W; Lyu Z; Sun W; Shao Y; Liu J; Yang Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 53(1):98-107. PubMed ID: 38105682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.